Fuchida SI - Search Results

1

Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.

Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S. Sunami K, et al. Among authors: fuchida si. Hematol Oncol. 2023 Aug;41(3):442-452. doi: 10.1002/hon.3105. Epub 2022 Dec 15. Hematol Oncol. 2023. PMID: 36433829 Clinical Trial.

2

[Thalidomide therapy in patients with refractory or relapsed multiple myeloma].

Ochiai N, Shimazaki C, Uchida R, Fuchida S, Okano A, Ashihara E, Inaba T, Fujita N, Adachi Y, Nishio A, Nakagawa M. Ochiai N, et al. Rinsho Ketsueki. 2002 Dec;43(12):1045-9. Rinsho Ketsueki. 2002. PMID: 12607993 Japanese.

3

CD5+ Epstein-Barr virus-positive intravascular large B-cell lymphoma in the uterus co-existing with huge myoma.

Yamada N, Uchida R, Fuchida S, Okano A, Okamoto M, Ochiai N, Iwasa H, Shimazaki C. Yamada N, et al. Am J Hematol. 2005 Mar;78(3):221-4. doi: 10.1002/ajh.20288. Am J Hematol. 2005. PMID: 15726593 Free article.

4

Malignant lymphoma presenting as a cardiac tumor and superior vena caval syndrome successfully treated by haploidentical stem cell transplantation.

Fuchida S, Yamada N, Uchida R, Okano A, Okamoto M, Ochiai N, Shimazaki C. Fuchida S, et al. Leuk Lymphoma. 2005 Oct;46(10):1517-21. doi: 10.1080/10428190500126596. Leuk Lymphoma. 2005. PMID: 16194899

5

Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Ochiai N, Yamada N, Uchida R, Fuchida S, Okano A, Hatsuse M, Okamoto M, Ashihara E, Shimazaki C. Ochiai N, et al. Int J Hematol. 2005 Oct;82(3):243-7. doi: 10.1532/IJH97.05049. Int J Hematol. 2005. PMID: 16207598 Clinical Trial.

6

[Progress in the management of multiple myeloma introduced by serum free light chain measurement].

Fuchida S, Shimazaki C. Fuchida S, et al. Nihon Rinsho. 2011 Dec;69(12):2267-73. Nihon Rinsho. 2011. PMID: 22242331 Japanese.

7

Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma.

Kiyota M, Kobayashi T, Fuchida S, Yamamoto-Sugitani M, Ohshiro M, Shimura Y, Mizutani S, Nagoshi H, Sasaki N, Nakayama R, Chinen Y, Sakamoto N, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Kuroda J, Taniwaki M. Kiyota M, et al. Int J Hematol. 2012 May;95(5):516-26. doi: 10.1007/s12185-012-1035-8. Epub 2012 Mar 17. Int J Hematol. 2012. PMID: 22426624

8

Serial measurement of free light chain detects poor response to therapy early in three patients with multiple myeloma who have measurable M-proteins.

Fuchida S, Okano A, Hatsuse M, Murakami S, Haruyama H, Itoh S, Shimazaki C. Fuchida S, et al. Int J Hematol. 2012 Nov;96(5):664-8. doi: 10.1007/s12185-012-1164-0. Epub 2012 Sep 2. Int J Hematol. 2012. PMID: 22941362

9

[Successful treatment with lenalidomide plus dexamethasone for multiple myeloma complicated with systemic amyloidosis].

Fuchida S, Okano A, Hatsuse M, Murakami S, Haruyama H, Shimazaki C. Fuchida S, et al. Rinsho Ketsueki. 2012 Nov;53(11):1937-9. Rinsho Ketsueki. 2012. PMID: 23257677 Review. Japanese.

10

[Primary retroperitoneal diffuse large B cell lymphoma with sclerosis mimicking idiopathic retroperitoneal fibrosis].

Hatsuse M, Fuchida S, Okano A, Murakami S, Haruyama H, Shimazaki C. Hatsuse M, et al. Rinsho Ketsueki. 2012 Dec;53(12):2018-20. Rinsho Ketsueki. 2012. PMID: 23318969 Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page